This analysis may help physicians understand which patients would benefit most from treatment with nivolumab.ĬheckMate 274 Combined positive score Nivolumab PD-L1 expression.Ĭopyright © 2023 The Author(s). DFS was impoved with nivolumab versus placebo for patients with TC ≥1%, CPS ≥1, and for patients with both TC <1% and CPS ≥1. We assessed the impact of levels of the protein PD-L1 expressed either on tumor cells (tumor cell score TC) or on both tumor cells and immune cells surrounding the tumor (combined positive score CPS). We studied survival time without cancer recurrence (disease-free survival DFS) for patients treated with nivolumab versus placebo after surgery to remove the bladder or components of the urinary tract for bladder cancer in the CheckMate 274 trial. These results may, in part, explain the mechanisms underlying a benefit with adjuvant nivolumab even in patients who had both TC <1% and CPS ≥1. In addition, patients with CPS ≥1 experienced improved DFS with nivolumab. More patients had CPS ≥1 than TC ≥1%, and most patients who had TC <1% had CPS ≥1. DFS was improved with nivolumab versus placebo for patients with TC ≥1% (hazard ratio 0.50, 95% confidence interval 0.35-0.71), those with CPS ≥1 (HR 0.62, 95% CI 0.49-0.78), and patients with both TC <1% and CPS ≥1 (HR 0.73, 95% CI 0.54-0.99). The global CheckMate -274 trial is investigating whether adjuvant Opdivo improves the outcomes of muscle-invasive urothelial cancer patients at high risk of recurrence after radical surgery. Among patients with TC <1%, 81% (n = 309) had CPS ≥1. CheckMate 274 (NCT02632409), a phase 3 trial of adjuvant nivolumab (NIVO) vs placebo (PBO) in high-risk muscle-invasive urothelial carcinoma (MIUC) after radical resection, demonstrated improved disease-free survival (DFS) with adjuvant NIVO vs PBO in the intent-to-treat (ITT) and tumor PD-L1 expression 1 populations. Tumor samples with both quantifiable CPS and TC were analyzed. CPS was determined retrospectively from previously stained slides. Primary endpoints were DFS in the intent-to-treat population and patients with tumor PD-L1 expression ≥1% using the tumor cell (TC) score. Outcome measurements and statistical analysis: We randomized a total of 709 patients 1:1 to nivolumab 240 mg or placebo every 2 wk intravenously for ≤1 yr of adjuvant treatment. To analyze DFS by combined positive score (CPS), which is based on PD-L1 expression in both tumor and immune cells. The CheckMate 274 trial demonstrated improved disease-free survival (DFS) with adjuvant nivolumab versus placebo in patients with muscle-invasive urothelial carcinoma at high risk of recurrence after radical surgery in both the intent-to-treat population and the subset with tumor programmed death ligand 1 (PD-L1) expression ≥1%.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |